M
M. Praet
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 26
Citations - 2638
M. Praet is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Hepatocellular carcinoma & Liver transplantation. The author has an hindex of 14, co-authored 26 publications receiving 2447 citations.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger,Halfdan Sorbye,Bengt Glimelius,Bengt Glimelius,Graeme J. Poston,Peter M. Schlag,Philippe Rougier,Wolf O. Bechstein,John N. Primrose,Euan Walpole,Meg Finch-Jones,Daniel Jaeck,Darius F. Mirza,Rowan W. Parks,Laurence Collette,M. Praet,U. Bethe,Eric Van Cutsem,Werner Scheithauer,Thomas Gruenberger +19 more
TL;DR: In this article, the authors compared the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.
Journal ArticleDOI
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Jean-Luc Van Laethem,Pascal Hammel,Françoise Mornex,David Azria,Geertjan van Tienhoven,Philippe Vergauwe,Marc Peeters,Marc Polus,M. Praet,Murielle Mauer,Laurence Collette,Volker Budach,Manfred B. Lutz,Eric Van Cutsem,Karin Haustermans +14 more
TL;DR: Adjuvant gemcitabine-based CRT is feasible, well-tolerated, and not deleterious; adding this treatment to full-dose adjuvant gem citabine after resection of pancreatic cancer should be evaluated in a phase III trial.
Journal ArticleDOI
Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease
Gillian R. Bullock,I Steyaert,G Bilbe,Robert M. Carey,Johan Kips,B De Paepe,Ra Pauwels,M. Praet,Helmy M. Siragy,M. de Gasparo +9 more
TL;DR: In patients with chronic obstructive pulmonary disease, there was a five- to sixfold increase in the ratio of AT1 to AT2 receptors in the regions of marked fibrosis surrounding the bronchioles, correlated well with the reduced lung function as expressed by the forced expiratory volume.
Journal ArticleDOI
Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
Alexander M.M. Eggermont,Stefan Suciu,Piotr Rutkowski,Jeremy Marsden,Mario Santinami,Philippa J. Corrie,Steinar Aamdal,Paolo A. Ascierto,Poulam M. Patel,Wim H. J. Kruit,Lars Bastholt,Lorenzo Borgognoni,Maria Grazia Bernengo,Neville Davidson,Larissa Polders,M. Praet,Alan Spatz +16 more
TL;DR: GM2-KLH/QS-21 vaccination does not improve outcome for patients with stage II melanoma and was stopped at the second interim analysis for futility regarding RFS and detrimental outcome regarding OS.
Journal ArticleDOI
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
Thierry Conroy,P.L. Etienne,Antoine Adenis,Michel Ducreux,Bernard Paillot,João Pedro Oliveira,J.F. Seitz,E. Francois,E. Van Cutsem,D.J.T. Wagener,F. Kohser,S. Daamen,M. Praet,Thierry Gorlia,Benoit Baron,Jaques Wils +15 more
TL;DR: Vinorelbine plus cisplatin represents a well-tolerated active palliative regimen for patients with advanced squamous cell carcinoma of the oesophagus and this combination may offer a better therapeutic index than cis platin-5-fluorouracil.